Melacine: Phase III data; marketed in Canada

CRXA said that its Phase III trial of Stage II melanoma patients who received Melacine or observation alone following surgical removal of their tumors did not show

Read the full 274 word article

How to gain access

Continue reading with a
two-week free trial.